Diasome to Present at the LifeSci Partners Summer Symposium

July 28, 2020
Diasome.comLatest UpdatesDiasome to Present at the LifeSci Partners Summer Symposium
Media Contact
Kent Manson
Diasome Pharmaceuticals

CLEVELAND – July 28, 2020 – Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin to prevent hypoglycemia for people living with diabetes, today announced that Robert Geho, Chief Executive Officer, will present a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners, on August 4 and 5, 2020. Please click the following link to register: https://lifesci.events/SummerSymposium

 

Presentation Details:

Date:                August 4, 2020

Time:                3:30pm Eastern Time

 

About Diasome

Diasome’s hepatocyte directed vesicle (HDV) technology is theonly pharmaceutical insulin additive being developed to prevent hypoglycemia by restoring normal liver physiology in patients with diabetes. HDV technology can be added to all forms of insulin to improve their safety and efficacy. For more information, visit www.diasome.com or follow us on Twitter.

 

Stay up-to-date with Diasome.

Enter your email address
Oops! Something went wrong while submitting the form.
10000 Cedar Avenue
Suite 6
Cleveland, OH 44106
+1.216.444.7110
info@diasome.com

Media Contact

Kent Manson
Kmanson@diasome.com
+1.720.891.7644